Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and AZD6738 in Metastatic Castration-Resistant Prostate Cancer
NCT03787680Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, ceralasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Michigan Rogel Cancer Center. Started Oct 2019; status: active, not recruiting.
02
Drugs
olaparibceralasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03787680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787680.